A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma
Latest Information Update: 05 Aug 2020
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenoid cystic carcinoma; Head and neck cancer
- Focus Therapeutic Use
- 26 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 26 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2019.
- 26 Sep 2018 Status changed from not yet recruiting to recruiting.